Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice

被引：46
作者：
Gil J. [1 ]
Leist M. [2 ]
Popovic N. [1 ]
Brundin P. [1 ]
Petersén Å. [1 ]
机构：
[1] Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, Lund
[2] Disease Biology, H. Lundbeck A/S, Copenhagen
来源：
BMC Neuroscience | / 5卷 / 1期
关键词：
Proliferate Cell Nuclear Antigen; Dentate Gyrus; BrdU Label Cell; BrdU Injection; Subependymal Layer;
D O I：
10.1186/1471-2202-5-17
中图分类号：
学科分类号：
摘要：
Background: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. Both excitotoxicity and oxidative stress have been proposed to play important roles in the pathogenesis of HD. Since no effective treatment is available, this study was designed to explore the therapeutic potential of erythropoietin (EPO), a cytokine that has been found to prevent excitotoxicity, and to promote neurogenesis. To avoid the side effects of a raised hematocrit, we used asialoerythropoietin (asialoEPO), a neuroprotective variant of EPO that lacks erythropoietic effects in mice. R6/2 transgenic HD mice were treated with this cytokine from five to twelve weeks of age. Results: We provide new evidence that cell proliferation in the dentate gyrus of the R6/2 hippocampus is reduced by 50% compared to wild-type littermate controls. However, we found that the asialoEPO treatment did not affect the progression of motor symptoms, weight loss or the neuropathological changes. Furthermore, cell proliferation was not enhanced. Conclusions: We conclude that the chosen protocol of asialoEPO treatment is ineffective in the R6/2 model of HD. We suggest that reduced hippocampal cell proliferation may be an important and novel neuropathological feature in R6 HD mice that could be assessed when evaluating potential therapies. © 2004 Gil et al, licensee BioMed Central Ltd.
引用
收藏
相关论文
共 52 条
[1]  
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell, 72, pp. 971-983, (1993)
[2]  
Li J.Y., Plomann M., Brundin P., Huntington's disease: A synaptopathy?, Trends. Mol. Med., 9, pp. 414-420, (2003)
[3]  
Petersen A., Brundin P., Huntington's disease: The mystery unfolds?, Int. Rev. Neurobiol., 53, pp. 315-339, (2002)
[4]  
Ciechanover A., Brundin P., The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg, Neuron., 40, pp. 427-446, (2003)
[5]  
Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, pp. 493-506, (1996)
[6]  
Menalled L.B., Chesselet M.F., Mouse models of Huntington's disease, Trends Pharmacol. Sci., 23, pp. 32-39, (2002)
[7]  
Hansson O., Petersen A., Leist M., Nicotera P., Castilho R.F., Brundin P., Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity, Proc. Natl. Acad. Sci. U S A, 96, pp. 8727-8732, (1999)
[8]  
Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P., Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation, Cell, 90, pp. 537-548, (1997)
[9]  
Cha J.H., Transcriptional dysregulation in Huntington's disease, Trends. Neurosci., 23, pp. 387-392, (2000)
[10]  
Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B., Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene, Proc. Natl. Acad. Sci. U S A, 95, pp. 6480-6485, (1998)
123456